Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
The company is hoping that the comprehensive solution will help bring on more pharma customers and offer extended opportunities for current users.
The Seattle-based immune cell sequencing firm saw sequencing revenues grow 38 percent while development revenues rose 65 percent.
B-cell receptor sequencing revealed lower-than-usual memory immune cell activity and more in unvaccinated children after measles virus infection.
Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
Personalis will analyze samples from the study, evaluating the pharma company's novel therapy INVAC-1 either as a monotherapy or in combination with the TKI ibrutinib.
The company hopes to convert biopharma customers to increasingly comprehensive approaches, and intends to branch out further with blood-based exome sequencing next year.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
The firms announced a deal to develop services and products for sequencing-based T cell and B cell receptor profiling in the US and Europe.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.